Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
98 hedge funds and large institutions have $343M invested in Intersect ENT, Inc in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 16 closing their positions.
20% more capital invested
Capital invested by funds: $286M → $343M (+$57.1M)
14% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 100 → 98 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
100% less call options, than puts
Call options by funds: $4K | Put options by funds: $1.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$8.14M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.78M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.97M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.4M |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$8.41M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.33M |
| 3 |
KIA
Kopp Investment Advisors
Bloomington,
Minnesota
|
-$6.12M |
| 4 |
Jennison Associates
New York
|
-$5.16M |
| 5 |
AC
Aisling Capital
New York
|
-$3.03M |
XENT Hedge Fund Activity: Q3 2016 in Review
98 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q3 2016, worth a combined $343M — up 20% from $286M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of XENT and 14 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 33 added.
The largest buyer was OppenheimerFunds, opening a new position worth an estimated $8.14M. The largest seller was Granahan Investment Management, cutting an estimated $8.41M.
- 98 institutional investors held Intersect ENT, Inc (XENT) as of Q3 2016, down from 100 in Q2 2016.
- Funds reported $343M of Intersect ENT, Inc stock for Q3 2016, up 20% quarter-over-quarter.
- 14 funds opened new Intersect ENT, Inc positions in Q3 2016 and 16 closed out, a net change of -2 holders.
- The largest Intersect ENT, Inc buyer in Q3 2016 was OppenheimerFunds, an estimated $8.14M added.
- The largest Intersect ENT, Inc seller in Q3 2016 was Granahan Investment Management, an estimated $8.41M sold.
Based on aggregated 13F filings for Q3 2016.